Table 1.
Characteristics of included studies.
| First Author (Year) [Reference] | Type of Condition | Trial Design | Number of Participants (Male/Female); Age (Mean ± SD) | Interventions | Morbidity Period (Mean ± SD or Range) | Outcome Index | Course of Treatment | Adverse Event (Case/Symptom) |
|||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trial | Control | Trial | Control | Trial | Control | ||||||
| Zhou (2002) [40] | Psoriasis vulgaris | Randomized; Single center; Parallel | 61 (37/24) 36.5 y |
36 (21/15) 38.7 y |
Yuyin capsule (18 caps, t.i.d) |
Compound amino-polypeptide tablets (10 caps, b.i.d) |
4.7 y | 4.3 y | 1.PASI 60 response rate | 8 w | Trial: 1 AE/ Control: 26 AEs/Thirst and xerostomia (8), xeroderma (7), desquamation (11) |
| Zhao (2003) [41] | Psoriasis vulgaris | Randomized; Single center; Parallel | 30 (19/11) Range 19~63 y |
30 (16/14) NR |
Xiaoyin decoction (200 mL, t.i.d) |
Compound Amino-polypeptide tablets (10 caps, b.i.d) |
Range 0.5~45 y | Range 0.5~45 y | 1.PASI 60 response rate | 8 w | Trial: 1 AE/Loose stool Control: 6 AEs/ xerostomia, xeroderma |
| Chen (2004) [42] | Psoriasis vulgaris | Randomized; Single center; Parallel | 61 (40/21) 37.51 ± 11.32 y |
55 (35/20) 35.13 ± 10.91 y |
Compound Qingdai pill (12 caps, t.i.d) |
Compound Amino-polypeptide tablets (10 caps, q.d or b.i.d) |
5.16 ± 5.02 y | 4.87 ± 4.71 y | 1.PASI 60 response rate | 8 w | Trial: 6 AEs/Nausea and anorexia Control: 21 AEs/including xerostomia, xeroderma |
| Lu (2005) [43] | Psoriasis vulgaris | Randomized; Single center; Parallel | 50 (32/18) 38.2 ± 16.4 y |
30 (19/11) 39.3 ± 17.1 y |
Yinxieling capsule (12~18 caps, t.i.d) |
Compound Amino-polypeptide tablets (10 caps, b.i.d) |
11.6 ± 8.4 y | 11.3 ± 8.1 y | 1. PASI 70 response rate | 8 w | Trial: 4 AEs/Gastrointestinal reaction Control: 22 AEs/Xerostomia, xeroderma, scale, pruritus |
| Liu (2005) [44] | Psoriasis vulgaris | Randomized; Single center; Parallel | 44 Both group (62/76) Range 17~64 y |
46 Both group (62/76) Range 17~64 y |
Jiedulaingxue decoction (b.i.d) |
Etretin (30 mg, t.i.d) |
NR | NR | 1. PASI 60 response rate | 4 w | Trial: No AE Control: pruritus and thirst (NR) |
| He (2005) [45] | Psoriasis vulgaris | Randomized; Single center; Parallel | 33 (18/15) Range 16~65 y |
30 (19/11) NR |
1. Antidote decoction (b.i.d) 2. Tretinoin |
1. Vitamin A [Retinol] (50,000 U, i.v., q.d) 2. Compound vitamin B tablets (6 caps, t.i.d) 3.Tretinoin |
Range 2 m~30 y | Range 40 d~28 y | 1. PASI 70 response rate | 4 w | NR |
| Qiu (2005) [46] | Psoriasis vulgaris | Randomized; Single center; Parallel | 32 (18/14) 30.42 ± 8.57 y |
32 (17/15) 33.34 ± 8.21 y |
Huoxuesanyuxiaoyin decoction (b.i.d) |
Acitretin (20 mg, b.i.d) |
6.53 ± 2.86 y | 7.04 ± 3.12 y | 1. PASI 60 response rate 2. PASI score |
8 w | Trial: 3 AEs/Diarrhea (2), constipation and vomiting (1) Control: Total AEs NR/Xerostomia, xeroderma, scale, dizziness, headache/AST, ALT elevation (3)/BUN elevation (1)/hyperlipidemia (5) |
| Li (2006) [47] | Psoriasis vulgaris | Randomized; Single center; Parallel | 43 (24/19) Range 13~55 y |
40 (27/13) Range 15~67 y |
1. Oral EAHM decoction (400 mL, b.i.d) 2. NB-UVB (0.3~0.5 J/cm2; 20%; NR; NR; q.o.d) |
1. Compound Amino-polypeptide tablets (15 tabs, t.i.d) 2. NB-UVB (0.3~0.5 J/ cm2; 20%; NR; NR; q.o.d) |
Range 1 m~42 y | Range 2 w~36 y | 1. PASI 60 response rate | 40 d | Trial: No AE Control: 5 AEs/Xerostomia, xeroderma, dizziness |
| Li (2008) [48] | Psoriasis vulgaris | Randomized; Single center; Parallel | 30 (19/11) 42.16 ± 11.26 y |
28 (18/10) 38.08 ± 9.64 y |
Qinzhu Liangxue decoction (30 mL, b.i.d) |
Compound amino-polypeptide tablets (15 tabs, t.i.d) |
5.16 ± 1.34 y | 6.28 ± 1.66 y | 1. PASI 60 response rate 2. DLQI |
4 w | NR |
| Ye (2008) [49] | Psoriasis vulgaris | Randomized; Single center; Parallel | 56 (38/18) Range 8~65 y |
56 (36/20) Range 9~68 y |
Zhixuejieduxiaoyin decoction (b.i.d) |
Compound amino -polypeptide tablets (15 tabs, t.i.d) |
NR | NR | 1. PASI 60 response rate | 8 w | Trial: 8 AEs/ Dizziness, anorexia, abdominal distention, abdominal pain Control: 22 AEs/ xerostomia, hot flush, xeroderma, scale, pruritus |
| Zhong (2008) [50] | Psoriasis vulgaris | Randomized; Single center; Parallel | 60 (39/21) 36.20 ± 10.74 y |
60 (43/17) 36.18 ± 10.82 y |
Xiaoyin granule (10.5 g, b.i.d) |
Compound amino-polypeptide tablets (15 taps, t.i.d) |
7.08 ± 4.46 y | 7.24 ± 4.33 y | 1. PASI 60 response rate 2. PASI score |
8 w | Trial 12 AEs/Xerostomia, gastrointestinal discomfort, nausea, loose stool (12) Control: Total AEs NR Xerostomia (12), aggravated pruritus (22), dyssebacia (15), scale at hand and foot (9), dermatitis (8),conjunctival injection (2), hypermenorrhea (3) |
| Hu (2009) [51] | Psoriasis vulgaris | Randomized; Single center; Parallel | 30 (16/14) 39.7 ± 11.7 y |
30 (17/13) 37.0 ± 11.7 ye |
Liangxue decoction (b.i.d) |
Compound Amino-polypeptide tablets (15 tabs, t.i.d) |
6.8 ± 3.4 y | 6.7 ± 3.8 y | 1.PASI 70 response rate 2.PASI score |
8 w | Trial: No AE Control: No AE |
| Wang (2009) [52] | Psoriasis vulgaris | Randomized; Single center; Parallel | 120 (65/55) Range 8~78 y |
116 (62/54) Range 9~75 y |
Baibi decoction (300 mL, b.i.d) |
Compound Amino-polypeptide tablets (10 tabs, b.i.d) |
Range 1 w~40 y | Range 1 w~35 y | 1. PASI 70 response rate | 90 d | NR |
| Feng (2009) [53] | Psoriasis vulgaris | Randomized; Single center; Parallel | 100 (60/40) 43.28 ± 12.01 y |
50 (30/20) 42.31 ± 11.08 y |
Wushe decoction (q.d) |
Compound econazole nitrate cream (b.i.d) |
8.67 ± 6.5 y | 8.23 ± 7.1 y | 1. PASI 60 response rate | Trial: 30 d Control: 21 d |
NR |
| Xie (2009) [54] | Psoriasis vulgaris | Randomized; Single center; Parallel | 41 (21/20) Mean 42.5 y |
30 (16/14) Mean 37.5 y |
Kangyin1 decoction (b.i.d) |
Acitretin (20 mg, b.i.d) |
Range 1 m~28 y | Range 4 m~21 y | 1. PASI score | 8 w | Trial: 2 AEs/Gastrointestinal discomfort (2) Control: 24 AEs/Xeroderma (23), ALT elevation (2), hyperlipidemia (2), Headache with tinnitus (1), gastrointestinal discomfort (2) |
| Hou (2009) [55] | Psoriasis vulgaris | Randomized; Single center; Parallel | 140 (72/68) 32.1 ± 6.6 y |
120 (63/57) 38.4 ± 5.9 y |
Huoxueliangxue decoction (b.i.d) |
Compound Amino-polypeptide tablets (10 tabs, b.i.d) |
Range 20 d~30 y | Range 15 d~32 y | 1. PASI 70 response rate 2. PASI score |
8 w | Trial: 5 AEs/diarrhea Control: 13 AEs/Xerostomia, (13), dizziness and drowsy (2) |
| Ho (2010) [56] | Plaque vulgaris | Randomized; Multi center; Parallel | 21 (14/7) 48.52 y |
20 (18/2) 43.45 y |
Wen-tong- hua-yu formulation |
1.Methotrexate (2.5~5 mg 1st week, increased to 10 mg q.w, not to exceed 30 mg q.w) 2.Folic acid (5 mg, q.d) |
NR | NR | 1. PASI score | 24 w | Trial: 48% reported/Infection, gastrointestinal side effects, a few developed abnormalities in liver function Control: 65% reported/Nausea, vomiting, increased liver enzyme level |
| Si (2010) [57] | Psoriasis vulgaris | Randomized; Single center; Parallel | 66 (28/38) 37.61 ± 14.43 y |
59 (23/35) 34.25 ± 12.66 y |
1. Jiawei Xiaoyaosan 2. Pulian ointment 3. NB-UVB (0.5 J/cm2; t.i.week) |
1. Acitretin (20 mg, qd) 2. Pulian ointment 3. NB-UVB (0.5 J/cm2; t.i.week) |
4.25 ± 5.06 y | 3.40 ± 4.77 y | 1. PASI 60 response rate | 4 w | NR |
| Yan (2010) [39] | Psoriasis vulgaris | Randomized; Single center; Parallel | 28 (Other information NR) | 28 (Other information NR) | Quyin decoction (300 mL, b.i.d) |
Placebo | NR | NR | 1. PASI 60 response rate | 12 w | NR |
| Ma (2010) [58] | Psoriasis vulgaris | Randomized; Single center; Parallel | 52 (28/24) 39.04 ± 18.58 y |
51 (26/25) 40.67 ± 13.64 y |
Yinxiebing fang decoction (b.i.d) |
Acitretin (30 mg, t.i.d) |
4.82 ± 7.29 y | 2.74 ± 3.32 y | 1. PASI 60 response rate 2. PASI score |
12 w | Trial: 5 AEs/Gastrointestinal discomfort (5) Control: Total AEs NR/Cheilitis (25), headache (6), tinnitus (2)/Gastrointestinal discomfort, liver function abnormality (4), xerostomia and scale (34), hyperlipidemia (8) |
| Ma (2011) [59] | Psoriasis vulgaris | Randomized; Single center; Parallel | 40 (22/18) Mean 35.3 y |
40 (23/17) Mean 37.8 y |
Keyin Ⅰ prescription (300 mL, b.i.d) |
Acitretin (30 mg, q.d; after 3rd week 60 mg, q.d) |
7.8 y | 8.3 y | 1. PASI 60 response rate 2. TNF-α |
90 d | Trial: No AE Control: 12 AEs/Cheilitis (3), pruritus and scale (7), Nausea with abdominal pain (2) |
| Wang (2011) [60] | Psoriasis vulgaris | Randomized; Single center; Parallel | 30 (17/13) 35.24 ± 10.28 y |
30 (16/14) 33.48 ± 10.02 y |
Tufulingqingdai decoction (300 mL, b.i.d) |
Compound Amino-polypeptide tablets (10 tabs, b.i.d) |
6.5 y | 5.4 y | 1. PASI 60 response rate 2. PASI score |
4 w | NR |
| Xie (2012) [61] | Psoriasis vulgaris | Randomized; Single center; Parallel | 42 (22/20) Mean 41.5 y |
30 (16/14) Mean 36.5 y |
Liangxie Runfu decoction (b.i.d) | Acitretin (20 mg, b.i.d) |
Range 1 m~25 y | Range 5 m~22 y | 1. PASI score | 12 w | Trial: 5 AEs/Gastrointestinal discomfort (5) Control: 25 AEs/Gastrointestinal discomfort (3), xerostomia and xeroderma (21), hyperlipidemia (1) |
| Jia (2012) [62] | Psoriasis vulgaris | Randomized; Single center; Parallel | 30 (18/12) 35.67 ± 8.86 y |
30 (16/14) 35.67 ± 8.86 y |
Xiaobi decoction (300 mL, t.i.d) |
Acitretin (20~30 mg, b.i.d or t.i.d) |
8.13 ± 1.35 y | 7.59 ± 1.46 y | 1. PASI 70 response rate 2. PASI score |
12 w | Trial: 9 AEs/Nausea (5), anorexia (2), loose stool (2) Control: 49 AEs/Nausea (6), anorexia (2), xeroderma (37), hyperlipidemia (4) |
| Cheng (2012) [63] | Psoriasis vulgaris | Randomized; Single center; Parallel | 35 (13/22) Range 3~18 y |
30 (10/20) Range 4~17 y |
EAHM prescription for individual clinical trial (b.i.d) | 1. Penicilin 2. Cephalosporin |
NR | NR | 1. PASI 70 response rate | 4 w | Trial: No AE Control: No AE |
| Ma (2012a) [64] | Psoriasis vulgaris | Randomized; Single center; Parallel | 41 (23/18) Mean 45.3 y |
37 (21/16) Mean 44.8 y |
Liangxue jiedu decoction (300 mL, b.i.d) | Compound Amino-polypeptide tablets (10 tabs, b.i.d) |
Range 5 m~5 y | Range 5 m~5 y | 1. PASI 70 response rate | 8 w | NR |
| Ma (2012b) [65] | Psoriasis vulgaris | Randomized; Single center; Parallel | 52 (28/24) 39.04 ± 18.58 y |
51 (26/25) 40.67 ± 13.64 y |
Yinxiaobing decoction | Acitretin (30 mg, t.i.d) |
4.82 ± 7.29 y | 2.74 ± 3.32 y | 1. PASI 60 response rate 2. PASI score |
12 w | Trial: 5 AEs/ Gastrointestinal discomfort (5) Control: 77 AEs/ Cheilitis (25), headache (6), tinnitus (2), abnormality of liver function (4), xeroderma and scale (34), hyperlipidemia (8) |
| Zhang (2013) [66] | Psoriasis vulgaris | Randomized; Single center; Parallel | 30 (19/11) 40.83 ± 6.48 y |
30 (18/12) 44.30 ± 5.80 y |
Blood cooling decoction (300 mL, b.i.d) |
Acitretin (20 mg, b.i.d) |
6.24 ± 1.48 y | 5.49 ± 1.24 y | 1. PASI 70 response rate | 8 w | NR |
| Liu (2013) [67] | Psoriasis vulgaris | Randomized; Single center; Parallel | 31 (18/13) 40.55 ± 12.83 y |
31 (16/15) 38.84 ± 10.57 y |
Wanbi decoction (300 mL, b.i.d) |
Acitretin (6 caps, b.i.d) |
9.45 ± 5.07 y | 7.80 ± 4.93 y | 1. PASI 60 response rate 2. PASI score |
Trial: 56 d Control: 60 d |
Trial: No AE Control: No AE |
| Xu (2013a) [68] | Psoriasis vulgaris | Randomized; Single center; Parallel | 24 (15/9) 44.78 ± 4.13 y |
24 (16/8) 44.13 ± 4.46 y |
1. Shufengyangtxue decoction (b.i.d) 2. Calcipotriol ointment (b.i.d) |
1. Metotrexate (5 mg, b.i.d, continuous three days in a week) 2. Calcipotriol ointment (b.i.d) |
101.53 ± 63.01 m | 102.65 ± 63.01 m | 1. PASI 60 response rate 2. PASI score |
8 w | Trial: 1 AE/ Gastrointestinal discomfort (1) Control: 3 AEs/Gastrointestinal discomfort (3), loose stool (1) |
| Xu (2013b) [69] | Psoriasis vulgaris | Randomized; Single center; Parallel | 59 (28/31) 41.26 ± 12.26 y |
56 (26/30) 39.42 ± 10.87 y |
Qingre Liangxue decoction (400 mL, b.i.d) | Acitretin (0.5 mg/kg, q.d) |
6.24 ± 1.48 y | 5.49 ± 1.24 y | 1. PASI 70 response rate | 6 w | Trial: 5 AEs/Gastrointestinal discomfort Control: 29 AEs/Gastrointestinal discomfort, cheilitis and scale |
| Zhu (2014) [70] | Psoriasis vulgaris | Randomized; Single center; Parallel | 30 (14/16) 43.53 ± 2.15 y |
30 (15/15) 43.75 ± 2.66 y |
1. Dahuang Zhechong Capsule (4 caps, b.i.d) 2. Vitamin E cream (b.i.d) |
1. Acitretin (30 mg, b.i.d−20 mg, 10 mg) 2. Vitamin E cream (b.i.d) |
19.23 ± 2.33 y | 18.17 ± 3.02 y | 1. PASI 70 response rate 2. PASI score |
12 w | Trial: No AE Control: 4 AEs/Xerostomia and xeroderma (3), elevation of liver enzyme (1) |
| Chen (2014) [71] | Psoriasis vulgaris | Randomized; Single center; Parallel | 30 (16/14) 32.45 ± 24.89 y |
30 (18/12) 31.73 ± 24.65 y |
Liangxue No.1 formula (b.i.d) | 1. Clobetasol propionate cream (t.i.d) 2. Loratadine (10 mg, q.d) 3. Acitretin (30 mg, q.d) |
14.12 ± 4.76 y | 14.58 ± 3.73 y | 1. PASI 60 response rate | 4 w | Trial: 1 AE/Nausea with vomiting Control: 12 AEs/Cheilitis, xerostomia, headache |
| Qian (2014) [72] |
Psoriasis vulgaris | Randomized; Single center; Parallel | Both group 74 (43/31) 23.1 ± 2.6 y Trial: 38 |
Both group 74 (43/31) 23.1 ± 2.6 y Control: 36 |
1. Liangxue Runfu decoction (b.i.d) 2.15% urea cream (b.i.d) |
1. Acitretin (20 mg, b.i.d) 2.15% urea cream (b.i.d) |
5.2 ± 1.8 y (Both group) | 5.2 ± 1.8 y (Both group) | 1. PASI 60 response rate | 8 w | Trial: 3 AEs/Gastrointestinal discomfort (3), xeroderma (2) Control: 9 AEs/Xerostomia (2), xeroderma (4), hyperlipidemia (2), gastrointestinal discomfort (1) |
| Peng (2014) [73] | Psoriasis vulgaris | Randomized; Single center; Parallel | Both group 86 (45/41) 51.36 ± 4.22 y Trial: 43 |
Both group 86 (45/41) 51.36 ± 4.22 y Control: 43 |
Liangxue Jiedu decoction (300 mL, b.i.d) | Compound amino-polypeptide tablets (15 tabs, t.i.d) |
9 ± 3.2 y (Both group) | 9 ± 3.2 y (Both group) | 1. PASI score | 12 w | NR |
| Dou (2014) [74] | Psoriasis vulgaris | Randomized; Single center; Parallel | 33 (21/12) 38.6 ± 11.9 y |
30 (19/11) 36.2 ± 12.5 y |
1. Wutengxiaoyin Decoction 2.10% urea cream (b.i.d) |
1. Compound amino-polypeptide Tablets (15 tabs, t.i.d) 2.10% urea cream (b.i.d) |
13.4 ± 12.5 y | 14.3 ± 8.7 y | 1. PASI 60 response rate 2. PASI score 3. DLQI |
8 w | Trial: 3 AEs/Gastrointestinal discomfort (2), diarrhea (3) Control: 19 AEs/ Xeroderma, xerostomia, scale (19), pruritus (4) |
| Miao (2014) [75] | Psoriasis vulgaris | Randomized; Single center; Parallel | Both group 198 (118/80) 39.6 ± 8 y Trial: 132 |
Both group 198 (118/80) 39.6 ± 8 y Control: 66 |
Quyin decoction (b.i.d) |
Acitretin (10 mg, t.i.d) | Mean 3.9 y (Both group) | Mean 3.9 y (Both group) | 1. PASI 70 response rate | 12 w | Trial: 12 AEs/Headache with dizziness (8), nausea and vomiting (6), liver function abnormality (3) Control: 35 AEs/ Xerostomia (25), xerophtalmia (18), xeroderma (14), pruritus (6), headache and dizziness (6), ALT elevation (8) |
| Xu (2015) [76] | Psoriasis vulgaris | Randomized; Single center; Parallel | 40 (23/17) 58.6 ± 8.8 y |
40 (19/21) 59.8 ± 9.3 y |
Liangxue Jiedu Decoction (300 mL, t.i.d) |
Acitretin (25 mg, b.i.d) |
12.5 ± 2.6 y | 13.7 ± 2.1 y | 1. PASI 70 response rate 2. PASI score |
8 w | Trial: No AE Control: 15 AEs/Xerostomia, gastrointestinal discomfort (6), pruritus and scale (9) |
| Zhang (2015) [77] | Psoriasis vulgaris | Randomized; Single center; Parallel | 60 (38/25) 31.29 ± 0.04 y |
65 (35/30) Mean 29.22 y |
Ziyinqingrexiaofeng san (NR) |
1. Acitretin (20 mg, b.i.d) 2. Compound Flumetasone ointment (b.i.d) |
Range 3 m~10 y | Range 1~12 y | 1. PASI 60 response rate | 8 w | Trial: 8 AEs/Burningsensation (5), erythema (2), aggravated pruritus (1) Control: NR |
| Yang (2015) [78] | Psoriasis vulgaris | Randomized; Single center; Parallel | 55 (32/23) 37.6 ± 3.3 y |
55 (30/25) 37.9 ± 3.5 y |
Qingre liangxue decoction (b.i.d) |
Acitretin (0.5 mg/kg, q.d) |
8.8 ± 0.7 y | 8.6 ± 0.5 y | 1. PASI score | 4 w | Trial: 2 AEs/Gastrointestinal discomfort (2) Control: 3 AEs/ Xerostomia (2), scale (1) |
| Liang (2015) [79] | Psoriasis vulgaris | Randomized; Single center; Parallel | 30 (16/14) 34.28 ± 10.26 y |
30 (18/12) 33.46 ± 10.12 y |
1. Tufuling Qingdai decoction (300 mL, b.i.d) 2.Vaseline (b.i.d) |
1. Compound amino-polypeptide tablets (10 tabs, b.i.d) 2. Vaseline (b.i.d) |
Mean 6.8 y | Mean 5.6 y | 1. PASI 60 response rate 2. PASI score 3. TNF-α |
4 w | NR |
| Han (2015) [80] | Psoriatic pustules | Randomized; Single center; Parallel | 30 (17/13) 37.71 ± 12.8 y |
30 (16/14) 36.48 ± 12.34 y |
Huayin Jiedu decoction (b.i.d) |
Acitretin (20 mg, b.i.d) |
8.64 ± 5.43 y | 8.51 ± 7.89 y | 1. PASI score | 8 w | Trial: No AE Control: 5 AEs/Elevated triacylglycerols |
| Xiang (2016) [81] | Psoriasis vulgaris | Randomized; Single center; Parallel | 30 (16/14) 37.5 ± 7.5 y |
30 (17/13) 37.8 ± 7.2 y |
Qinzhu Liangxue decoction (400 mL, b.i.d) | Acitretin (20~30 mg, b.i.d or t.i.d) |
10.23 ± 7.2 y | 11.23 ± 8.2 y | 1. PASI score 2.IL-17 3.IL-23 |
4 w | NR |
| Wang (2016) [82] | Psoriasis vulgaris | Randomized; Single center; Parallel | 50 (28/22) 27.2 ± 5.2 y |
50 (27/23) 27.3 ± 6.2 y |
Liangxue Runfu decoction (t.i.d) | Acitretin (10 mg, b.i.d) |
NR | NR | 1. PASI 60 response rate 2. TNF-α |
NR | NR |
| Zhou (2016) [83] | Psoriasis vulgaris | Randomized; Single center; Parallel | 82 (46/36) 35.7 ± 9.4 y |
82 (48/34) 36.2 ± 9.7 y |
Shufeng jiedu capsules (12 caps, t.i.d) | Compound amino-polypeptide tablets (6 tabs, b.i.d) |
4.2 ± 2.1 y | 4.1 ± 2.2 y | 1. PASI 70 response rate | 12 w | NR |
| Du (2016a) [84] | Psoriasis vulgaris | Randomized; Single center; Parallel | 80 (56/24) 47.3 ± 10.3 y |
80 (56/21) 48.7 ± 13.3 y |
Shengdi Baimao decoction (300 mL, b.i.d) | 0.025% Tretinoin ointment (b.i.d) |
2.3 ± 1.8 y | 2.5 ± 1.7 y | 1. PASI 60 response rate 2. TNF-α |
20 d | Trial: No AE Control: No AE |
| Du (2016b) [85] | Psoriasis vulgaris | Randomized; Single center; Parallel | 24 (14/10) 41.75 ± 9.03 y |
24 (15/9) 42.11 ± 10.95 y |
Heat-clearing and detoxicating oral liquid (60 mL, t.i.d) |
Acitretin (30 mg, t.i.d) |
6.7 ± 4.4 y | 7.1 ± 5.2 y | 1. PASI 60 response rate 2. TNF-α |
12 w | NR |
| Mao (2017) [86] | Psoriasis vulgaris | Randomized; Single center; Parallel | 30 (21/9) 48.96 ± 6.88 y |
30 (22/8) 48.02 ± 7.18 y |
1. Xiaoyinfang (200 mL, b.i.d) 2. NB-UVB |
1. Calcipotriol ointment (b.i.d) 2. NB-UVB |
3.77 ± 1.27 y | 3.62 ± 1.07 y | 1. PASI 70 response rate 2. IL-17 3. IL-23 |
8 w | NR |
| Xia (2018) [87] | Psoriasis vulgaris | Randomized; Single center; Parallel | 36 (21/15) 37.25 ± 13.44 y |
34 (23/11) 34.85 ± 12.01 y |
Kanli fang (400 mL, b.i.d) | 0.005% Calcipotriol ointment (q.d) |
7.57 ± 7.25 y | 7.57 ± 7.25 y | 1. PASI score | 6 w | Trial: No AE Control: 3 AEs/Burning sense (3) |
| Li (2018) [88] | Psoriasis vulgaris | Randomized; Single center; Parallel | 33 (19/14) 35.52 ± 3.72 y |
33 (18/15) 35.48 ± 3.62 y |
Jianpi Jiedu decoction (400 mL, b.i.d) |
Acitretin (40 mg, b.i.d) |
6.42 ± 3.65 y | 6.35 ± 3.45 y | 1. PASI 60 response rate 2. DLQI 3. TNF-α |
NR | NR |
| Yang (2018) [89] | Psoriasis vulgaris | Randomized; Single center; Parallel | 35 (18/17) 33.89 ± 2.68 y |
35 (17/18) 34.26 ± 2.91 y |
Jinji Xiaoyin granule (27 g, t.i.d) |
Acitretin (40 mg, b.i.d) |
3.62 ± 3.21 y | 3.26 ± 3.42 y | 1. PASI 70 response rate 2. PASI score 3. IL-17 4. IL-23 5.TNF-α |
8 w | NR |
| Wang (2019) [90] | Psoriasis vulgaris | Randomized; Single center; Parallel | 36 (20/16) 41.4 ± 3.5 y |
36 (18/18) 39.2 ± 2.4 y |
Qingying decoction (300 mL, b.i.d) |
Acitretin (20 mg, b.i.d) |
15.1 ± 3.5 y | 14.2 ± 27 y | 1. PASI 60 response rate 2. PASI score 3. DLQI 4. IL-17 5. IL-23 |
12 w | NR |
| Zhang (2019) [91] | Psoriasis vulgaris | Randomized; Single center; Parallel | 48 (28/20) 36.84 ± 6.20 y |
48 (28/20) 36.60 ± 6.20 y |
Xijiao Dihuang decoction (300 mL, b.i.d) | Acitretin (20 mg, b.i.d) |
56.53 ± 12.30 m | 57.20 ± 12.50 m | 1. PASI 70 response rate 2. PASI score |
12 w | NR |
| Jiang (2019) [92] | Psoriasis vulgaris | Randomized; Single center; Parallel | 30 (18/12) 20.15 ± 2.55 y |
30 (14/16) 15.34 ± 4.71 y |
1. Xijiao Dihuang Jiedu decoction (q.d) 2. Urea ointment for external use (b.i.d.) |
1. Roxithromycin (Adlut: 300 mg, b.i.d; Adolescent: 2.5~5 mg*kg, b.i.d) 2. Urea ointment for external use (b.i.d.) |
NR | NR | 1. PASI 70 response rate 2. PASI score |
2 w | Trial: No AE Control: No AE |
| Wen (2019) [93] | Psoriasis vulgaris | Randomized; Single center; Parallel | 38 (26/12) 33.42 ± 8.37 y |
38 (23/15) 31.44 ± 7.42 y |
Xiaobi decoction (b.i.d) |
Acitretin (40 mg, b.i.d) |
46.87 ± 15.10 m | 43.07 ± 15.98 m | 1. PASI score | 4 w | NR |
| Chen (2020) [94] | Psoriasis vulgaris | Randomized; Single center; Parallel | 20 (11/9) 33.65 ± 5.41 y |
20 (12/8) 33.58 ± 5.26 y |
1. Quyin decoction (200 mL, b.i.d) 2.10% Urea ointment |
1. Compound amino poly-peptide tables (10 tabs, b.i.d) 2. 10% Urea ointment |
10.25 ± 3.35 y | 10.19 ± 3.59 y | 1. PASI 60 response rate | NR | NR |
AE: Adverse event; b.i.d: bis in die; d: days; DLQI: Dermatology Life Quality Index; i.v: intravenous; IL-17: Interlukin-17; IL-23: Interlukin-23; m: months; mg: milligram; mL: milliliter; NR: Not reported; p.o: per os; PASI; psoriasis area severity index; q.d: quaque die; q.o.d: quaque altera die; q.w: quaque week; SD: standard deviation; t.i.d: ter in die; TNF-α: tumor necrosis factor alpha; U: unit; w: weeks; y: years.